Constitutive K-Ras G12D activation of ERK2 specifically regulates 3D invasion of human pancreatic cancer cells via MMP-1

Molecular Cancer Research

Volumn 10, Issue 2, 2012, Pages 183-196

  Botta, Gregory P ^a,b   Reginato, Mauricio J ^a   Reichert, Maximilian ^c   Rustgi, Anil K ^c   Lelkes, Peter I ^b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b DREXEL UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN E6; PROTEIN E7; RNA; SHORT HAIRPIN RNA; MAPK1 PROTEIN, HUMAN;

ARTICLE; BASEMENT MEMBRANE; CANCER CELL; CELL INVASION; CELL STRUCTURE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MEMBRANE MODEL; MICROARRAY ANALYSIS; ONCOGENE K RAS; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; TUMOR MICROENVIRONMENT; CANCER INVASION; CELL CULTURE; DNA MICROARRAY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; ONCOGENE RAS; PANCREAS DUCT; PANCREAS TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION;

CELLS, CULTURED; ENZYME ACTIVATION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, RAS; HUMANS; MATRIX METALLOPROTEINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 1; MUTATION; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC DUCTS; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84857223882     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-11-0399     Document Type: Article

References (58)

1. Keleg S, Büchler P, Ludwig R, Büchler MW, Friess H. Invasion and metastasis in pancreatic cancer. Mol Cancer 2003;2:14.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
3. Rustgi AK. The molecular pathogenesis of pancreatic cancer: clarifying a complex circuitry. Genes Dev 2006;20:3049-53. (Pubitemid 44790620)
4. Drosten M, Dhawahir A, Sum EY, Urosevic J, Lechuga CG, Esteban LM, et al. Genetic analysis of Ras signaling pathways in cell proliferation, migration, and survival. EMBO J 2010;29:1091-104.
5. Lowy AM, Leach SD, Philip P. Pancreatic cancer. New York: Spring Science + Business Media, LLC; 2008.
6. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291-310. (Pubitemid 46763022)
7. Friday BB, Adjei AA. K-ras as a target for cancer therapy. Biochim Biophys Acta 2005;1756:127-44.
8. Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009;69:4286-93.
9. Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A 2010;107:1-6.
10. Frese KK, Tuveson DA. Maximizing mouse cancer models. Nat Rev Cancer 2007;7:645-58. (Pubitemid 47327410)
11. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-61.
12. Lee KM, Nguyen C, Ulrich AB, Pour PM, Ouellette MM. Immortalization with telomerase of the Nestin-positive cells of the human pancreas. Biochem Biophys Res Commun 2003;301:1038-44. (Pubitemid 36279217)
13. Campbell PM, Groehler AL, Lee KM, Ouellette MM, Khazak V, Der CJ, et al. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res 2007;67: 2098-106. (Pubitemid 46424228)
14. Yip-Schneider MT, Lin A, Barnard D, Sweeney CJ, Marshall MS. Lack of elevated MAP kinase (Erk) activity in pancreatic carcinomas despite oncogenic K-ras expression. Int J Oncol 1999;15:271-9.
15. Nelson CM, Bissell MJ. Modeling dynamic reciprocity: engineering three-dimensional culture models of breast architecture, function, and neoplastic transformation. Semin Cancer Biol 2005;15:342-52. (Pubitemid 41140304)
16. Botta GP, Manley P, Miller S, Lelkes PI. Real-time assessment of three-dimensional cell aggregation in rotating wall vessel bioreactors in vitro. Nat Protoc 2006;1:2116-27. (Pubitemid 46778061)
17. Yamada KM, Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell 2007;130:601-10. (Pubitemid 47268064)
18. Mahadevan D, von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 2007;6:1186-97. (Pubitemid 46711982)
19. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010;141:52-67.
20. O'Brien LE, Tang K, Kats ES, Schutz-Geschwender A, Lipschutz JH, Mostov KE. ERK and MMPs sequentially regulate distinct stages of epithelial tubule development. Dev Cell 2004;7:21-32. (Pubitemid 39172685)
21. Yang E, Boire A, Agarwal A, Nguyen N, O'Callaghan K, Tu P, et al. Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Res 2009;69:6223-31.
22. Jimi S, Shono T, Ono M, Kuwano M, Tanaka M, Lopezotin C, Kono A. Expression of matrix metalloproteinases 1 and 2 genes in a possible association with metastatic abilities of human pancreatic cancer cells. Int J Oncol 1997;10:623-8. (Pubitemid 27122032)
23. Chu GC, Kimmelman AC, Hezel AF, DePinho RA. Stromal biology of pancreatic cancer. J Cell Biochem 2007;101:887-907. (Pubitemid 47040870)
24. Nakae H, Endo S, Inoue Y, Fujino Y, Wakabayashi G, Inada K, et al. Matrix metallo-proteinase-1 and cytokines in patients with acute pancreatitis. Pancreas 2003;26:134-8. (Pubitemid 36278300)
25. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, Adsay NV, Shen-Ong GL, Berg K, et al. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 2003;63:8614-22. (Pubitemid 38064035)
26. Endo H, Watanabe T, Sugioka Y, Niioka M, Inagaki Y, Okazaki I. Activation of two distinct MAPK pathways governs constitutive expression of matrix metalloproteinase-1 in human pancreatic cancer cell lines. Int J Oncol 2009;35:1237-45.
27. Shankar J, Messenberg A, Chan J, Underhill TM, Foster LJ, Nabi IR. Pseudopodial actin dynamics control epithelial-mesenchymal transition in metastatic cancer cells. Cancer Res 2010;70:3780-90.
28. Gilles C, Polette M, Zahm JM, Tournier JM, Volders L, Foidart JM, et al. Vimentin contributes to human mammary epithelial cell migration. J Cell Sci 1999;113:4615-25. (Pubitemid 30034810)
29. Schoumacher M, Goldman RD, Louvard D, Vignjevic DM. Actin, microtubules, and vimentin intermediate filaments cooperate for elongation of invadopodia. J Cell Biol 2010;189:541-56.
30. Shin S, Dimitri C, Yoon SO, Dowdle W, Blenis J. ERK2 but not ERK1 induced epithelial-to-mesenchymal transformation via DEF motifdependent signaling events. Mol Cell 2010;38:114-27.
31. Burkhard KA, Chen F, Shaprio P. Quantitative analysis of ERK2 interactions with substrate proteins, roles for kinase docking domains and activity in determining binding affinity. J Biol Chem 2011;286:2477-85.
32. Doehn U, Hauge C, Frank SR, Jensen CJ, Duda K, Nielsen JV, Cohen MS, et al. RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile/invasive gene program and phenotype in epithelial cells. Mol Cell 2009;35:511-22.
33. Hancock CN, Macias A, Lee EK, Yu SY, Mackerell AD Jr, Shapiro P. Identification of novel extracellular signal-regulated kinase docking domain inhibitors. J Med Chem 2005;48:4586-95. (Pubitemid 40993419)
34. Vantaggiato C, Formentini I, Bondanza A, Bonini C, Naldini L, Brambilla R. ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially. J Biol 2006;5:14.
35. Lefloch R, Pouyssegur J, Lenormand P. Single and combined silencing of ERK1 and ERK2 reveals their positive contribution to growth signaling depending on their expression levels. Mol Cell Biol 2008; 28:511-27.
36. Jesnowski R, Fürst D, Ringel J, Chen Y, Schrödel A, Kleef J, et al. Immortalization of pancreatic stellate cells as an in vitro model of pancreatic fibrosis: deactivation is induced by Matrigel and N-acetylcysteine. Lab Invest 2005;85:1276-91. (Pubitemid 41348642)
37. Veit C, Genze F, Menke A, Hoeffert S, Gress TM, Gierschik P. Activation of phosphatidylinositol 3-kinase and extracellular signal-regulated kinase is required for glial cell line-derived neurotrophic factor-induced migration and invasion of pancreatic carcinoma cells. Cancer Res 2004;64:5291-300. (Pubitemid 39006549)
38. Nelson CM, Bissell MJ. Of extracellular matrix, scaffolds, and signaling; tissue architecture regulates development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2006;22:287-309.
39. Weigelt B, Lo AT, Park CC, Gray JW, Bissell MJ. HER2 signaling pathway activation and response of breast cancer cells to HER2- targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat 2010;122:35-43.
40. Webber MM, Bello D, Kleinman HK, Hoffman MP. Acinar differentiation by non-malignant immortalized human prostatic epithelial cells and its loss by malignant cells. Carcinogenesis 1997;18:1225-31. (Pubitemid 28132514)
41. Tolde O, Rosel D, Vesely P, Folk P, Brabek J. The structure of invadopodia in a complex 3D environment. Eur J Cell Biol 2010;89:674-80.
42. Walsh N, Clynes M, Crown J, O'Donovan N. Alterations in integrin expression modulates invasion of pancreatic cancer cells. J Exp Clin Cancer Res 2009;28:140-52.
43. Javle MM, Gibbs JF, Iwata KK, Pak Y, Rutledge P, Yu J, et al. Epithelialmesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-ERK) in surgically resected pancreatic cancer. Ann Surg Oncol 2007;14:3527-33. (Pubitemid 350160113)
44. Blick T, Hugo H, Widodo E, Waltham M, Pinto C, Mani SA, et al. Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. J Mammary Gland Biol Neoplasia 2010; 15:235-52.
45. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999;18: 813-22. (Pubitemid 29080340)
46. Dhanasekaran DN, Kashef K, Lee CM, Xu H, Reddy EP. Scaffold proteins of MAP-kinase modules. Oncogene 2007;26:3185-202. (Pubitemid 46763014)
47. Sawai H, Okada Y, Funahashi H, Matsuo Y, Takahashi H, Takeyama H, et al. Activation of focal adhesion kinase enhances the adhesion and invasion of pancreatic cancer cells via extracellular signal-regulated kinase-1/2 signaling pathway activation. Mol Cancer 2005;4:37.
48. Schaeffer HJ, Catling AD, Eblen ST, Collier LS, Krauss A, Weber MJ, et al. MP1: a MEK binding partner that enhances enzymatic activation of the MAP Kinase cascade. Science 1998;281:1668-71. (Pubitemid 28435581)
49. Yan C, Boyd DD. Regulation of matrix metalloproteinase gene. J Cell Physiol 2007;211:19-26.
50. Wu JY, Lu H, Sun Y, Graham DY, Cheung HS, Yamaoka Y. Balance between polyoma enhancing activator 3 and activator protein 1 regulates Helicobacter pylori-stimulated matrix metalloproteinase 1 expression. Cancer Res 2006;66:5111-20. (Pubitemid 43844933)
51. Jones LE, Humphreys MJ, Campbell F, Neoptolemos JP, Boyd MT. Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res 2004;10: 2832-45. (Pubitemid 38509163)
52. Shields MA, Dangi-Garimella S, Krantz SB, Bentrem DJ, Munshi HG. Pancreatic cancer cells respond to type I collagen by inducing snail expression to promote membrane type 1 matrix metalloproteinase- dependent collagen invasion. J Biol Chem 2011;286: 10495-504.
53. Zucker S, Cao J. Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: ready for prime time? Cancer Biol Ther 2009; 8:2371-3.
54. Utani A, Momota Y, Endo H, Kasuya Y, Beck K, Suzuki N, et al. Laminin α3 LGF4 module induces matrix metalloproteinase-1 through mitogen-activated protein kinase signaling. J Biol Chem 2003;278: 34483-90. (Pubitemid 37553296)
55. Durko M, Navab R, Shibata HR, Brodt P. Suppression of basement membrane type IV collagen degradation and cell invasion in human melanoma cells expressing an antisense RNA for MMP-1. Biochim Biophys Acta 1997;1356:271-80. (Pubitemid 27226732)
56. Chung L, Dinakarpandian D, Yoshida N, Lauer-Fields JL, Fields GB, Visse R, et al. Collagenase unwinds triple-helical collagen prior to peptide bond hydrolysis. EMBO J 2004;23:3020-30. (Pubitemid 39093596)
57. Pasternak RD, Hubbs SJ, Caccese RG, Marks RL, Conaty JM, DiPasquale G. Interleukin-1 stimulates the secretion of proteoglycan- and collagen-degrading proteases by rabbit articular chondrocytes. Clin Immunol Immunopathol 1986;41:351-67. (Pubitemid 17207528)
58. Poincloux R, Collin O, Lizarraga F, Romao M, Debray M, Piel M, et al. Contractility of the cell rear drives invasion of breast tumor cells in 3D Matrigel. Proc Natl Acad Sci U S A 2011;208:1943-8.